Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alkermes plc (NASDAQ:ALKS – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among […]
Addiction Recovery Care announced ARC Healthcare Chief Operating Officer Pat Fogarty will see a role expansion.
Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder.
18.01.2024 - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness. “Serge” as he was known ...
StockNews.com began coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research report report published on Tuesday. The brokerage issued a strong-buy rating on the stock. A number of other brokerages have also recently issued reports on ALKS. Mizuho reduced their price objective on Alkermes from $37.00 to $35.00 and set a buy […]